| WO2021213924 |
BioNTech, Germany |
Coronavirus RNA vaccine
encoding SARS-CoV-2 spike protein for
preventing COVID-19 |
| WO2020190750 |
Moderna,
U.S. Dept. of Health and Human Services, USA |
Preparation
of HIV Env- and lentivirus Gag protein-encoding
mRNA VLP vaccine to induce broad-spectrum neutralizing antibodies
for treating HIV infection |
| WO2018151816 |
Moderna, USA |
Immunogenic compositions for Zika virus including cationic
lipid nanoparticles encapsulating mRNA having an open reading frame
encoding a viral, bacterial or parasitic antigen, a pan HLA DR-binding
epitope (PADRE) and a 5′ terminal cap modified to increase
mRNA translation efficiency |
| WO2021155243 |
Moderna, USA |
Respiratory virus vaccine compositions |
| WO2013055905 |
Novartis, Switzerland |
Recombinant self-replicating polycistronic RNA molecules expressing
multiple herpes virus proteins and their use in vaccines for inducing
neutralizing antibodies |
| WO2021159040 |
Moderna, USA |
Engineering SARS CoV-2 mRNA
vaccines expressing key neutralizing domains of spike protein, individually
or in combination, for inducing protective immunity and immunotherapy |
| WO2021251453 |
Daiichi Sankyo, University of Tokyo, Japan |
Nucleic
acid lipid particle vaccine encapsulated with severe
acute respiratory syndrome coronavirus 2 messenger ribonucleic acid |
| WO2021159130 |
Moderna, USA; U.S. Dept. of Health and Human Services, USA |
Preparation of SARS CoV-2 mRNA
vaccines encoding full-length spike protein variant, stabilized into
a prefusion conformation, encapsulated in a lipid nanoparticle formulation |
| WO2021255270 |
Ziphius Vaccines, Belgium; Universiteit Gent, Belgium |
Self-amplifying COVID-19 RNA
vaccine encoding SARS-CoV-2 Spike and
Nucleocapsid protein antigen and alphavirus Nonstructural protein |
| WO2017070613 |
Moderna, USA |
Human cytomegalovirus RNA vaccines |
| WO2021204179 |
Suzhou Abogen Biosciences, China |
Nucleic acid
vaccines for coronavirus |
| WO2021226436 |
Translate Bio, USA; Sanofi, France |
Optimized
nucleotide sequences encoding SARS-COV-2 antigens |
| WO2017070623 |
Moderna, USA |
Herpes simplex virus RNA
vaccine |
| WO2021160346 |
Institut Pasteur, France |
Nucleic acid
vaccine against severe acute respiratory syndrome
coronavirus SARS-CoV-2 |
| WO2022171182 |
Stemirna
Therapeutics, China |
Vaccine reagent for treating or
preventing coronavirus mutant
strain |
| CA3132188 |
Providence Therapeutics Holdings, Canada |
Compositions and methods for the prevention and/or treatment
of COVID-19 |
| WO2021183563 |
Arcturus
Therapeutics, USA |
Coronavirus vaccine compositions and
methods |
| WO2022150717 |
Moderna, USA |
Seasonal RNA influenza
virus vaccines |
| WO2022129918 |
Imperial College, UK Innovations Ltd, U.K. |
Engineering a thermally stabilized self-amplifying RNA vaccine
based on Venezuelan Equine Encephalitis virus backbone encoding SARS-CoV-2 spike glycoprotein encapsulated in lipid
nanoparticle formulation for preventing and/or treatment of COVID-19 |
| WO2022178196 |
Sanofi Pasteur, USA |
Meningococcal B recombinant vaccine |
| WO2022137133 |
CureVac,
Germany; GlaxoSmithKline Biologicals SA, U.K. |
RNA vaccine
against SARS-CoV-2 variants |
| WO2022116528 |
Suzhou CureMed Biomedical Technology, China |
Circular
RNA vaccine containing circular RNA and kit for detecting
novel coronavirus neutralizing antibody |
| US20220325255 |
University of Texas,
USA |
Compositions and methods for treating viral infections
targeting
TRIM7 |
